-
EP3750530
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3750530
| EP3750530 - COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 24.09.2021 Database last updated on 31.08.2024 | |
| Former | Request for examination was made Status updated on 18.06.2021 | ||
| Former | The application has been published Status updated on 13.11.2020 | Most recent event Tooltip | 05.07.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states TyrNovo Ltd. One Azrieli Center Round Tower, 23rd Floor 132 Menachem Begin Road 6701101 Tel Aviv / IL | [2020/51] | Inventor(s) | 01 /
REUVENI, Hadas 15 Nof Harim Street 9083600 Har Adar / IL | 02 /
HAVIV, Izhak 18 Brazil Street, Apt. 7 Tel-Aviv 6946028 / IL | 03 /
KUPERSHMIDT, Lana 69 Keren Hayesod Street 11/11 2705312 Kiryat Bialik / IL | [2020/51] | Representative(s) | Straus, Alexander 2K Patent- und Rechtsanwälte Bajuwarenring 14 82041 Oberhaching / DE | [N/P] |
| Former [2020/51] | Straus, Alexander 2K Patent- und Rechtsanwälte - München Keltenring 9 82041 Oberhaching / DE | Application number, filing date | 20168234.1 | 04.02.2016 | [2020/51] | Priority number, date | US201562112257P | 05.02.2015 Original published format: US 201562112257 P | US201562136530P | 22.03.2015 Original published format: US 201562136530 P | [2020/51] | Previously filed application, date | WO2016IL50134 | 04.02.2016 | [2020/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3750530 | Date: | 16.12.2020 | Language: | EN | [2020/51] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 23.10.2020 | Classification | IPC: | A61K31/165, A61K31/436, A61K31/505, A61K31/517, A61K31/519, A61K39/00, A61P35/00 | [2020/51] | CPC: |
A61K31/165 (EP,CN,IL,KR,US);
A61K39/39558 (CN,IL,US);
A61K45/06 (CN,IL);
A61K31/145 (CN,IL);
A61K31/4184 (CN,IL);
A61K31/436 (EP,IL,KR,US);
A61K31/437 (CN,IL);
A61K31/4375 (EP,IL,US);
A61K31/44 (CN,IL);
A61K31/4523 (CN,IL);
A61K31/505 (EP,IL,KR,US);
A61K31/506 (CN,IL);
A61K31/517 (EP,IL,KR,US);
A61K31/519 (EP,CN,IL,KR,US);
A61K31/5415 (CN,IL);
A61P35/00 (EP,CN,IL);
A61P35/02 (EP,CN,IL);
C07K16/2863 (CN,IL,US);
| C-Set: |
A61K31/145, A61K2300/00 (CN);
A61K31/165, A61K2300/00 (CN,US,EP);
A61K31/4184, A61K2300/00 (CN);
A61K31/436, A61K2300/00 (US,EP);
A61K31/437, A61K2300/00 (CN);
A61K31/44, A61K2300/00 (CN);
A61K31/4523, A61K2300/00 (CN);
A61K31/505, A61K2300/00 (US,EP);
A61K31/506, A61K2300/00 (CN);
A61K31/517, A61K2300/00 (US,EP);
A61K31/519, A61K2300/00 (EP,US,CN);
A61K31/5415, A61K2300/00 (CN); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/29] |
| Former [2020/51] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | KOMBINATIONEN VON IRS/STAT3-DOPPELMODULATOREN UND ANTIKREBSMITTEL ZUR BEHANDLUNG VON KREBS | [2020/51] | English: | COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER | [2020/51] | French: | COMBINAISONS DE DOUBLES MODULATEURS D'IRS/STAT3 ET D'AGENTS ANTICANCÉREUX POUR LE TRAITEMENT DU CANCER | [2020/51] | Examination procedure | 14.06.2021 | Amendment by applicant (claims and/or description) | 14.06.2021 | Examination requested [2021/29] | 14.06.2021 | Date on which the examining division has become responsible | 23.09.2021 | Despatch of a communication from the examining division (Time limit: M04) | 31.01.2022 | Reply to a communication from the examining division | 19.12.2022 | Despatch of a communication from the examining division (Time limit: M06) | 27.06.2023 | Reply to a communication from the examining division | 05.03.2024 | Despatch of a communication from the examining division (Time limit: M04) | 04.07.2024 | Reply to a communication from the examining division | Parent application(s) Tooltip | EP16746247.2 / EP3253733 | Fees paid | Renewal fee | 06.04.2020 | Renewal fee patent year 03 | 06.04.2020 | Renewal fee patent year 04 | 06.04.2020 | Renewal fee patent year 05 | 25.02.2021 | Renewal fee patent year 06 | 28.01.2022 | Renewal fee patent year 07 | 27.01.2023 | Renewal fee patent year 08 | 26.02.2024 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XDI]WO2012090204 (NOVOTYR THERAPEUTICS LTD [IL], et al) [XD] 1-15 * page 11 - page 13 * * page 30 - page 36 * * page 53 - page 54; example 7 * [I] 1-15; | [XDI]WO2012117396 (NOVOTYR THERAPEUTICS LTD [IL], et al) [XD] 1-15 * page 53; claim 1 * * figures 3,4,5A *[I] 1-15 | by applicant | US5217999 | US5773476 | WO2008068751 | WO2009147682 | WO2012090204 | WO2012117396 | - LEVITZKI et al., Science, (19950000), vol. 267, pages 1782 - 88 | - LEVITZKI et al., Biochem. Pharm., (19900000), vol. 40, pages 913 - 920 | - LEVITZKI et al., FASEB J., (19920000), vol. 6, pages 3275 - 3282 | - POSNER et al., Mol. Pharmacol., (19940000), vol. 45, pages 673 - 683 | - YAISH et al., Science, (19880000), vol. 242, pages 933 - 935 | - GAZIT et al., J. Med. Chem., (19890000), vol. 32, pages 2344 - 2352 | - YONEDA et al., Cancer Res., (19910000), vol. 51, pages 4430 - 4435 | - LI et al., J. Med. Chem., (20090000), vol. 52, no. 16, pages 4981 - 5004 | - PAZDUR et al., Principles of Oncologic Pharmacotherapy, (20050000), pages 23 - 42 | - FREIEDER, Cancer medicine, (20030000), vol. 11, pages 817 - 837 | - BUCK E. et al., "Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors", Cancer Res., (20081015), vol. 68, no. 20, pages 8322 - 32 | - BERGE et al., J. Pharm. Sci., (19770000), vol. 66, pages 1 - 19 | - CARDONE et al., Science, (19980000), vol. 282, pages 1318 - 1321 | - BUCHWALD et al., Surgery, (19800000), vol. 88, page 507 | - SAUDEK et al., N. Engl. J. Med., (19890000), vol. 321, page 574 | - KOLHO et al., J. Med. Virol., (19930000), vol. 40, no. 4, pages 318 - 21 | - TING et al., Transplantation, (19780000), vol. 25, no. 1, pages 31 - 3 | - KENIRY M.PARSONS R., Cancer Discovery, (20110000), vol. 1, pages 203 - 204 | - VILLANUEVA et al., Cancer Cell, (20100000), vol. 18, pages 683 - 95 |